Loading…
Loading…
IEIH (iShares Evolved U.S. Innovative Healthcare ETF) is no longer actively trading.
This usually means the fund has been liquidated, merged into another product, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
The fund invests, under normal circumstances, at least 80% of its net assets in U.S. listed common stock of large-, mid- and small-capitalization pharmaceutical and biotechnology companies. It will hold common stock of those companies that fall into the Innovative Healthcare Evolved Sector which have economic characteristics that have been historically correlated with companies traditionally defined as pharmaceutical and biotechnology companies. The fund is non-diversified.
Is IEIH's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Johnson & Johnson continued its long streak of earnings beat. It outpaced revenue estimates as well but cut its full-year guidance on a strong dollar.
Pharma and biotech ETFs are in great shape and are trading at a one-month high level.
The issuer typically closes a handful of funds during the month every year.
The pandemic-driven supply chain woes and the resultant red-hot inflation, the Russia-Ukraine war and the resultant hit to the commodity market as well as the central banks' policy tightening in the developed world may cause global growth slowdown in the coming days.
Uncertainties are playing a big role in the Wall Street due to record-high inflation, Fed policy tightening and Omicron strain of coronavirus. Still, some ETFs may warm up your winter portfolio.